Quick answer
Permian Resources Corporation (PR) reported revenue of $5.07B and net income of $935.2M for the fiscal year ended 2025-12-31, up 1.3% from $5.00B the year before, per its 10-K filed with the SEC on 2026-02-26. Long-term debt stood at $3.55B.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $5.07B | $935.2M | $3.55B |
| 2024 (FY ending 2024-12-31) | $5.00B | $984.7M | $4.18B |
| 2023 (FY ending 2023-12-31) | $3.12B | $476.3M | $3.85B |
| 2022 (FY ending 2022-12-31) | $2.13B | $515.0M | $2.14B |
| 2021 (FY ending 2021-12-31) | $1.03B | $138.2M | $825.6M |
| 2020 (FY ending 2020-12-31) | $580.5M | -$682.8M | $1.07B |
| 2019 (FY ending 2019-12-31) | $944.3M | $15.8M | $1.06B |
| 2018 (FY ending 2018-12-31) | $891.0M | $199.9M | $691.6M |
| 2017 (FY ending 2017-12-31) | $429.9M | $75.6M | $390.8M |
Related
- PODD revenue, net income and debt history (Insulet Corporation)
- PPG revenue, net income and debt history (Ppg Industries Inc)
- PPL revenue, net income and debt history (PPL Corp)
- PRU revenue, net income and debt history (Prudential Financial Inc)
- PSA revenue, net income and debt history (Public Storage)
- PSX revenue, net income and debt history (Phillips 66)
- PTC revenue, net income and debt history (PTC Inc.)
- PTGX revenue, net income and debt history (Protagonist Therapeutics, Inc)
Last updated 2026-10-16. Data only, not financial or tax advice.